Hims & Hers Secures Exclusive Access to FDA-Approved Oral GLP-1 Weight Loss Pill and More
Hims & Hers Health, Inc. has taken a major step in the consumer health space, announcing a partnership with Novo Nordisk to provide eligible U.S. customers access to a comprehensive suite of FDA-approved GLP-1 medications—including the only FDA-approved GLP-1 weight loss pill. This development cements Hims & Hers’ status as the largest global platform for affordable, approved GLP-1 medication access.
Broader Selection and Affordable Pricing Set the Platform Apart
Under the agreement, Hims & Hers subscribers can now access Novo Nordisk's GLP-1s at prices starting as low as $149 per month (medication costs not including membership fees). Options available immediately include:
| Medication | Form | Dosages | Indication |
|---|---|---|---|
| Wegovy® (semaglutide) | Injection | 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg; 7.2 mg coming soon | Weight loss |
| Wegovy® (semaglutide) | Pill | 1.5 mg, 4 mg, 9 mg, 25 mg | Weight loss |
| Ozempic® (semaglutide) | Injection pen | 0.25 mg, 0.5 mg, 1 mg, 2 mg | Type 2 diabetes* |
*Ozempic is not FDA-approved for weight loss.
Outcomes and Eligibility: Up to 20% Weight Loss Potential
The clinical data supporting these medications are compelling: based on independent provider decisions, eligible customers could lose up to 20% of their body weight with GLP-1 treatment, complemented by nutrition guidance and exercise. Results from clinical studies indicate average weight loss of 14–19% over 64–72 weeks, with individual results varying.
Membership Model Delivers Comprehensive and Personalized Support
Hims & Hers has also introduced a new weight-loss membership program starting at $39 for the first month ($149/month thereafter), designed to offer:
- 24/7 direct access to providers
- Personalized nutrition plans
- Ongoing clinical check-ins
- Peer support in the Hers Weight Loss community
Medication costs are separate and may be covered under HSA or FSA plans. Subscribers gain access to special savings and personalized care decisions.
Platform Flexibility: Compounded GLP-1s Available When Clinically Necessary
For a limited group whose needs aren’t met by FDA-approved therapies, Hims & Hers plans to offer access to compounded GLP-1s at a provider’s discretion, ensuring continuity of care even as its FDA-approved assortment grows more robust.
Main Takeaway: Hims & Hers Strengthens Its Position as an Affordable, Accessible GLP-1 Leader
This collaboration marks a substantial advance in the online health platform space, enabling Hims & Hers to offer the broadest access to FDA-approved GLP-1 options—further bolstered by its multifaceted support services and straightforward pricing. While the long-term business impact is yet to play out, this initiative positions the company as a leader in comprehensive, customer-first weight loss and diabetes care.
For those tracking consumer health trends, the Hims & Hers/Novo Nordisk alliance is worth monitoring as prescribed GLP-1 adoption accelerates and telehealth platforms evolve.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI